Backed by NIH, DNA Nanobots aims to disrupt gene therapy with scalable, non-viral platform—$5M round now open to select investors. We're at a pivotal moment, with platform validation and NIH support, ...

HAMPTON, England--(BUSINESS WIRE)--Touchlight, a CDMO enabling the development of genetic medicines with its enzymatic doggybone DNA (dbDNA) technology, today announced that the Company has used its ...

Biodistribution of nonviral cationic vector/DNA complexes was studied after systemic or intratracheal administration to the lungs and correlated with transgene expression. Intravenous injection in ...

HAMPTON, England--(BUSINESS WIRE)--Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion ...

The plasmid DNA manufacturing market offers significant opportunities due to the outsourcing trend and rising demand in ...

Many biotech and pharmaceutical companies focused on mRNA manufacturing experience challenges associated with their plasmid DNA (pDNA) supply, including slow or delayed production and poor or ...

Every dog has its day, and Monday was Curia’s as the CDMO got its paws on a new drug manufacturing platform. Curia has enlisted enzymatic DNA production outfit Touchlight to furnish its clients with ...

Touchlight, an enzymatic DNA production company, completed the redevelopment and expansion of its U.K. manufacturing facility, housed in a repurposed Victorian waterworks on the banks of the River ...

Researchers found that PD-1-enhanced DNA vaccination can induce sustained virus-specific CD8+ T cell immunity in an AIDS monkey model. The vaccinated monkeys remained free of AIDS for six years and ...